Fuji Pharma Co., Ltd.

Tokyo Stock Exchange 4554.T

Fuji Pharma Co., Ltd. Total Non-Current Liabilities for the year ending September 30, 2024: USD 60.12 M

Fuji Pharma Co., Ltd. Total Non-Current Liabilities is USD 60.12 M for the year ending September 30, 2024, a -37.54% change year over year. Total non-current liabilities are the sum of long-term debt and other non-current liabilities.

Fuji Pharma Co., Ltd. Total Non-Current Liabilities for the year ending September 30, 2023 was USD 96.26 M, a -11.57% change year over year.
Fuji Pharma Co., Ltd. Total Non-Current Liabilities for the year ending September 30, 2022 was USD 108.85 M, a 6.59% change year over year.
Fuji Pharma Co., Ltd. Total Non-Current Liabilities for the year ending September 30, 2021 was USD 102.12 M, a -2.08% change year over year.
Fuji Pharma Co., Ltd. Total Non-Current Liabilities for the year ending September 30, 2020 was USD 104.29 M, a 20.43% change year over year.

Key data

Date	Total Non-Current Liabilities	Shareholders' Equity	Other Liabilities	Total Liabilities

Tokyo Stock Exchange: 4554.T

Fuji Pharma Co., Ltd.

CEO	Mr. Toyoyuki Kamide
IPO Date	Feb. 22, 2010
Location	Japan
Headquarters	5-7 Sanban-cho
Employees	1,621
Sector	Healthcare
Industries Pharmaceuticals Biotechnology Cleaning Supplies Clinical Trials Cosmetics Drugstores & Retail Pharmacies Medical Instruments Personal Care

Description

Fuji Pharma Co., Ltd. engages in the research and development, manufacture, and marketing of pharmaceutical products in Japan and internationally. The company offers injection agents, internal drugs, drugs for external use, and diagnostic products. It also provides medical care for women; in vitro diagnostics, acute medical care products, and curative medicines; and information regarding pharmaceuticals and health. Fuji Pharma Co., Ltd. was incorporated in 1965 and is headquartered in Tokyo, Japan.

Key trends

Past 5 years